Antibiotics in addition to systemic corticosteroids for acute exacerbations of COPD

Department of Pulmonary Diseases, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.99). 10/2009; 181(2):150-7. DOI: 10.1164/rccm.200906-0837OC
Source: PubMed

ABSTRACT The role of antibiotics in acute exacerbations is controversial and their efficacy when added to systemic corticosteroids is unknown.
We conducted a randomized, placebo-controlled trial to determine the effects of doxycycline in addition to corticosteroids on clinical outcome, microbiological outcome, lung function, and systemic inflammation in patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease.
Of 223 patients, we enrolled 265 exacerbations defined on the basis of increased dyspnea and increased sputum volume with or without increased sputum purulence. Patients received 200 mg of oral doxycycline or matching placebo for 7 days in addition to systemic corticosteroids. Clinical and microbiological response, time to treatment failure, lung function, symptom scores, and serum C-reactive protein were assessed.
On Day 30, clinical success was similar in intention-to-treat patients (odds ratio, 1.3; 95% confidence interval, 0.8 to 2.0) and per-protocol patients. Doxycycline showed superiority over placebo in terms of clinical success on Day 10 in intention-to-treat patients (odds ratio, 1.9; 95% confidence interval, 1.1 to 3.2), but not in per-protocol patients. Doxycycline was also superior in terms of clinical cure on Day 10, microbiological outcome, use of open label antibiotics, and symptoms. There was no interaction between the treatment effect and any of the subgroup variables (lung function, type of exacerbation, serum C-reactive protein, and bacterial presence).
Although equivalent to placebo in terms of clinical success on Day 30, doxycycline showed superiority in terms of clinical success and clinical cure on Day 10, microbiological success, the use of open label antibiotics, and symptoms. Clinical trial registered with (NCT00170222).

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ADVERTIMENT. La consulta d'aquesta tesi queda condicionada a l'acceptació de les següents condicions d'ús: La difusió d'aquesta tesi per mitjà del servei TDX ( ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d'investigació i docència. No s'autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d'un lloc aliè al servei TDX. No s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora. ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR ( ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR (framing). Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la persona autora. WARNING. On having consulted this thesis you're accepting the following use conditions: Spreading this thesis by the TDX ( service has been authorized by the titular of the intellectual property rights only for private uses placed in investigation and teaching activities. Reproduction with lucrative aims is not authorized neither its spreading and availability from a site foreign to the TDX service. Introducing its content in a window or frame foreign to the TDX service is not authorized (framing). This rights affect to the presentation summary of the thesis as well as to its contents. In the using or citation of parts of the thesis it's obliged to indicate the name of the author.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Traffic congestion is one of the leading causes of lost productivity and decreased standard of living in urban settings. Recent advances in artificial intelligence suggest vehicle navigation by autonomous agents will be possible in the near future. In this paper, we propose a reservation-based system for alleviating traffic congestion, specifically at intersections, and under the assumption that the cars are controlled by agents. First, we describe a custom simulator that we have created to measure the different delays associated with conducting traffic through an intersection. Second, we specify a precise metric for evaluating the quality of traffic control at an intersection. Using this simulator and this metric, we show that our reservation-based system can perform two to three hundred times better than traffic lights. As a result, it can smoothly handle much heavier traffic conditions. We show that our system very closely approximates an overpass, which is the optimal solution for the problem with which we are dealing.
    3rd International Joint Conference on Autonomous Agents and Multiagent Systems (AAMAS 2004), 19-23 August 2004, New York, NY, USA; 01/2004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Not Available
    Autonomous Agents and Multiagent Systems, 2004. AAMAS 2004. Proceedings of the Third International Joint Conference on; 02/2004
Show more